Drug Search Results

Vimnerixin

Alternative Names: Vimnerixin, azd-4721, rist-4721, azd4721, azd 4721, rist4721
Latest Update: 2023-03-22
Latest Update Note: Clinical Trial Update

Product Description

Vimnerixin (AZD4721/RIST4721 ) is an orally bioavailable CXC chemokine receptor type 2 antagonist. It has minimal activity on CXCR1, so has little effect on neutrophil activation. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12100)

Mechanisms of Action: CXCR2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aristea Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vimnerixin

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Palmoplantar Pustulosis

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
RIST4721 in Subjects with Palmoplantar Pustulosis	P2	Active, not recruiting	Palmoplantar Pustulosis	2024-02-28

Recent News Events

Date	Type	Title
02/10/2023	News Article	Aristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the Company
02/07/2023	PubMed	CXCR2 Antagonist RIST4721 Acts as a Potent Chemotaxis Inhibitor of Mature Neutrophils Derived from Ex Vivo-Cultured Mouse Bone Marrow.
11/02/2022	News Article	Aristea Therapeutics Strengthens its Team with Appointments of Executive Medical Director and Two Clinical Scientists as Clinical Programs Progress
08/30/2022	News Article	Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa
08/24/2022	News Article	Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer
03/01/2022	PubMed	Possible Extraction of Drugs from Lung Tissue During Broncho-alveolar Lavage Suggest Uncertainty in the Procedure's Utility for Quantitative Assessment of Airway Drug Exposure.
12/01/2021	PubMed	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions